Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Net Margin (2016 - 2025)

Arrowhead Pharmaceuticals' Net Margin history spans 16 years, with the latest figure at 10.7% for Q4 2025.

  • For Q4 2025, Net Margin rose 701942.0% year-over-year to 10.7%; the TTM value through Dec 2025 reached 21.41%, up 2600281.0%, while the annual FY2025 figure was 3.63%, 1717324.0% up from the prior year.
  • Net Margin reached 10.7% in Q4 2025 per ARWR's latest filing, up from 6.29% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 67.78% in Q1 2025 to a low of 7008.72% in Q4 2024.
  • Average Net Margin over 5 years is 809.91%, with a median of 165.54% recorded in 2021.
  • Peak YoY movement for Net Margin: crashed -374551bps in 2023, then soared 701942bps in 2025.
  • A 5-year view of Net Margin shows it stood at 229.13% in 2021, then soared by 71bps to 66.82% in 2022, then crashed by -5605bps to 3812.33% in 2023, then plummeted by -84bps to 7008.72% in 2024, then surged by 100bps to 10.7% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Net Margin are 10.7% (Q4 2025), 6.29% (Q3 2025), and 643.4% (Q2 2025).